0.3981
-0.0045
(-1.12%)
As of 1:18:34 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.02 | -0.03 | -0.16 | -0.1 |
| Low Estimate | -0.02 | -0.03 | -0.16 | -0.1 |
| High Estimate | -0.02 | -0.03 | -0.16 | -0.1 |
| Year Ago EPS | -0.01 | 0.01 | -0.07 | -0.16 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | 50.28M | 48.11M | 184.87M | 204.04M |
| Low Estimate | 49.3M | 44.3M | 171.2M | 171.9M |
| High Estimate | 51.26M | 51.92M | 202.07M | 220.72M |
| Year Ago Sales | 56.52M | 67.49M | 228.61M | 184.87M |
| Sales Growth (year/est) | -11.04% | -28.71% | -19.13% | 10.37% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.03 | -0.06 | -0.06 | -0.03 |
| EPS Actual | -0.01 | 0.01 | -0.05 | -0.02 |
| Difference | 0.02 | 0.07 | 0.01 | 0.01 |
| Surprise % | 66.67% | 116.67% | 16.67% | 33.33% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.02 | -0.03 | -0.16 | -0.1 |
| 7 Days Ago | 0 | 0 | -0.22 | -0.16 |
| 30 Days Ago | 0 | 0 | -0.22 | -0.16 |
| 60 Days Ago | 0 | 0 | -0.22 | -0.16 |
| 90 Days Ago | 0 | 0 | -0.22 | -0.16 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | 1 |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| AMRN | -100.00% | -400.00% | -128.57% | 37.50% |
| S&P 500 | 6.56% | 6.52% | 9.72% | 14.29% |
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 6/20/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 6/18/2024 |
| Downgrade | Jefferies: Buy to Hold | 10/25/2023 |
| Maintains | Goldman Sachs: Sell to Sell | 7/20/2023 |
| Maintains | Northland Capital Markets: Market Perform to Market Perform | 7/19/2023 |
| Upgrade | Jefferies: Hold to Buy | 1/6/2023 |
Related Tickers
SCLX Scilex Holding Company
0.2559
-0.85%
BIIB Biogen Inc.
119.29
-3.00%
AZN AstraZeneca PLC
65.05
-4.98%
GSK GSK plc
34.48
-5.61%
SNY Sanofi
49.89
-4.02%
GILD Gilead Sciences, Inc.
105.52
-1.62%
RHHBY Roche Holding AG
35.58
-5.50%
OGN Organon & Co.
12.66
-2.99%
BAYRY Bayer Aktiengesellschaft
5.46
-0.91%
BMY Bristol-Myers Squibb Company
54.22
-1.95%